ArticleNPJ precision oncology2026
Habitat-based CT radiomics profiling spatial-temporal heterogeneity in resectable NSCLC predict pathological response to neoadjuvant chemoimmunotherapy: a multi-center study.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The profound spatial and temporal heterogeneity of non-small cell lung cancer (NSCLC) drives unpredictable responses to neoadjuvant chemoimmunotherapy (NCI), highlighting the need for effective predictive biomarkers to optimize treatment. In this multicenter study, we evaluated the ability of habitat imaging to predict major pathological response (MPR) to NCI by capturing spatial-temporal tumor heterogeneity, using pre- and post-treatment CT scans from 394 patients with resectable non-small cell lung cancer across three institutions. A radiomics-based predictive framework integrating global texture descriptors, spatial heterogeneity features, and longitudinal imaging information was constructed to distinguish pathological responders from non-responders. Models based on global texture or spatial heterogeneity features alone achieved areas under the receiver operating characteristic curve (AUCs) ranging from 0.71 to 0.80 across validation cohorts, whereas the integrated model further improved discrimination, achieving an AUC of up to 0.85 in external validation. These findings demonstrate that habitat imaging provides a robust approach for predicting MPR and supporting patient stratification and personalized treatment planning in NSCLC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.